IntelGenx Technologies (IGXT) 12 Aug 222022 Q2 Earnings call transcript

Good day everyone and welcome to today’s IntelGenx Second Quarter 2022 Financial Results Call. At this time all participants are in a listen-only mode. Later you will have an opportunity to ask questions during the question-and-answer session. [Operator Instructions] And it is now my pleasure to turn today’s program over to Stephen Kilmer, Investor Relations.

Thank you. thank joining and call. on everyone, afternoon, you us for today’s Good me Dr. are the With line on Horst CEO; Dr. Zerbe, CFO; and IntelGenx’s André Godin, President our and Corporate our the and Counsel. Intellectual Matzen, company’s President General Business Dana Vice Property and Tommy Legal VP, and Kenny, Affairs and of Development;

accordingly, subject mentioned mentioned, Details found in that assumptions and begin, turn we Canadian and, and made as undertake and the We forward-looking call of in may be forward-looking by U.S. to Horst? information amounts laws. on by assumptions today’s to commissions. results our can with Zerbe. us change. like in to expectations U.S. filings today you that be are Canadian to these may now update call subject risks, differ Before are may remind these dollars, represents securities do as obligation would number required and I’d Dr. any and except all securities risks materially. any of U.S. I to today the were are preparing our unless otherwise which A contain over statements, statements, forward-looking like not to

afternoon quarter for our I XXXX Good our review pipeline thank Steve. results. you, progress made corporate the second we’ve will provide joining conference projects. financial André second us on update key and Thank a for the call. you will On everyone Then call, quarter IntelGenx XXXX today’s and discuss

the Following line our will that for we open questions. up

of programs be today’s our update during development the Although brief. quarter, we corporate continue progress second will each to

was we we heavier which quarter. flow, be news as material this enter months, the four light will relatively Our expect

one September year, begin batch We programs. for the Exeltis we a met this clinical a there in anticipate me European additional in was materials commercialization positive start We shipped of will countries. potential most for manufacturing strong discuss completed in of and was May, study likely that let the later the The the Eastern ATAI. to quarter. study The for partner the the of third trial the indicating be we with call RIZAPORT interest report of with So in Exeltis with countries. still certain

in In for of discussions partners licensing are other rights we [indiscernible]. with distribution addition,

Moving IntelGenx task to to Aquestive formed a have had on CRL to received work force for Tadalafil, product. that the and joint the the Aquestive response on

of license Now, CBX of purchase to Heritage’s on resale expected cannabis producers we – XXXX we their order containing working revenue related in moving the our Control Canada our to our reflected to in that to the happen three expect results. films, in the for top September. to one is film be QX are CBD fulfill Accordingly, early to

listed website. partner product got – Mart CBD Canada Our distribution recently listing and the to drug the Shoppers Heritage in continues rush on

We the Scotia Corporation Canada continue discuss met questions for finally push Tommy during to available distribution [ph] to and will Liquor the in recently with as be litigation, Q&A the And two-way per session. Nova products.

the year, initially montelukast reported ongoing the efforts resumed. is to our have regarding and sites Recruitment as the six study, earlier and study on we moving BUENA in activated. correspondingly Now recruitment with

a XX completed randomized, patients have been treatment. As of which of now total of have XX

launched accelerate enrollment. We’re rate and a the diligently have to participants study recruitment and attract working improve now awareness to more Facebook campaign

results enrollment these in expected later XXXX. Final With of thus QX of we to be ongoing activities, complete are available study QX currently XXXX. in expect to

the to and the undisclosed partner are will a to in received Once further our report we program waiting a full Finally, animal trial partial film be product. better the study to discuss develop on study a tailored available, clinical dogs for animal in for recently batch health U.S. health, issued. delivered we based We results

will health companies fully animal despite In the with addition, by – new updating reflected discussions least now our we on better a not to trend. quarters. in that, like be coming this regarding we film which with of a I the is at platform. review the progress financial slow, not would make results. look over Again, a our expect several our you André And We progress forward quarter to continue short are call to in term turn we for André? to

Good Horst. everyone. you, Thank afternoon,

As June minutes company’s for few to the financial I’ll discuss ended the second take XX, Horst a performance mentioned, XXXX. quarter

to revenues quarter, expenses in royalties same versus R&D $XX,XXX. for were second the up $XXX,XXX, month million year. $X.X corresponding million and revenue is of amounted for period to the period the of Operating XXXX. an attributable total $XXX,XXX XXX% $X.X three of QX For in $XXX,XXX from increase and change mainly XXXX last The costs

QX last was of period to an $X.X $X.X basic the $X.XX period comparable per for to net For an operating loss compared period million million compared $X.X Zerbe. $X.X comparable QX for to was XXXX. will compared $X.X Adjusted had same call of XXXX. million company I of loss year. net million XXXX, of for $X.XX loss negative XXXX, turn share comprehensive and $X operating for loss million XXXX for comprehensive the Dr. million The the EBITDA diluted the the on now to of Horst? or or back QX the basis per share

So, thanks, André.

like I’d executing Thank over like call our would proceed for applied prepared following and you section, for questions. again long-term to team you. our statements both that turn the Q&A with we on to to Q&A. recognize the to remind will I I that, forward-looking the our strategy. our now once Before remarks And

from ahead comes go Please We’ll question that go first ahead. Instructions] [indiscernible]. to [Operator our

open. line Your is

and tell you been long. is Tadalafil that’s for me hold please too Hi, Can on happening good with what afternoon. RIZAPORT

like I’d Dana, Okay, or… you turn over to to

sure. for Yes,

we year launched RIZAPORT is for with a launched in And So know, partner well. the Product Spain. the product about as our product you ago. Exeltis doing is

those products Spain is RIZAPORT first is Maxzide, off know, As alternative you and the prescribed the molecule one is migraine to Rizatriptan might number the brand. in which

the completed four, really the product there. be happy are success story for months, to to waiting but months we the how far in see we’re with so performed first XX the quite XX So

we On our with year which are really the preparing this this we then FDA later probe. the side, the will accelerate submission CRL, meeting with to or response and with be to doing U.S. the

a coming, be year. should with is we program about some there the now all that as it questions prepare on is by with Tadalafil the released and little So APIs, have our were for the the we Aquestive. resolved end way of a U.S. at we partnered Talking to recently partner FDA issues that this And on before it’s and longer bit some us took batches some

partner to to us, preparing are So and the Aquestive we the CRL. respond

to a be joint have early work details and We plan and here That’s last really through project year. next team our well submit to as ready response. the to the is

because brand And is even aware let I me and Dana comment, one – is really new currently in can not the which just office. not he’s add

time We have us The FDA even initially and but a upon Like few I consultant months. approach decided submit the save and the that rather not and very meeting meeting our the FDA do that that a external to us decided by additional reason with this to that then our we waste said, will submit waste applying case response CRL, package, going directly. any months. data couple our discuss of not solid for time to will save by a who review being of for directly need to our to response have will

[indiscernible]. to responding that’s Yes,

When three eight And a least justify funds many XX product sorry, interrupt. monetizing our how And to years, years. will We’ve years not at we an with because bringing the are always and years Rizaport with lost been in actually to going think, are And I the we partner fruition into despite start now, to? get [indiscernible] opportunity Aquestive. or the over it does why and we mean we last assets lab? trying even market stuck raising in for, we’ve ever so

Well on understand I frustration. your Rizaport

We have ourselves, not been the progress time always with either. happy slow

Rizaport made. Dana. the just we’ve up very heard that stepped you As as it far I significantly, from And addition as

year. be where resubmission. Aquestive’s our the best know not formed is possibly very could we the jointly did was that which What responding to diligently with to with are Tadalafil, with of was besides NDA a clearing this under knowledge, is we that we path-to-market. impression would we decision back task XXX(b)(X) could the Spain, path and decision working years and that force towards our We’re accelerate that moving be already it very time next made on best product to on market to cooperate ago now And market the Aquestive U.S. complete on the joined make. On rapidly few Aquestive letter the a a know response was not the came will pretty the the in the significant will at now FDA was,

work. Our formulators that here are involved in

acknowledge bumps, but that path-to-market now swiftly. are has, some for or undoubtedly Tadalafil Tadalafil very and seen has right we’re the moving on path and the I So has had

to the we’re not So the as Tadalafil, on market. early And right. if mistaken be XXXX, expecting I’m product

from next Hugh Investor]. [Private Kelly question take our We’ll

is line Your open.

and my ANDA?, Yes, to the go visit on good they to send do in you everyone. when resubmission after Zerbe the Dr. have Thank do through afternoon, you new that plant you taking questions then FDA, for the for another inspection resubmit

It’s not a it’s it’s to XXX(b)(X) with, ANDA. an ANDA begin – not a new

That was my mistake.

You’re right.

Sorry about that.

They preapproval inspected inspection. they sure have not recently are The I’m well, to do mandatorily, they conduct problem. quite may quite facility. wrecks but not not might our not they no though clear. even Yes, very may another come or

they whether I actually or certainly question is that good we honestly, know. chance don’t that come prepared, and come not So be There certainty. that will a we with they but cannot do answer very will

to data testing that looking the stability on your with good all that. three follow-on And Okay. the batches, was

And mentioned this excellent. FDA. in main before and have that in, to They had responding reason directly we the prepared towards look the a I that bothering to remarks meeting decided with really to move why the not is area as

or We say, cannot that convincing data very have possibly we do raise as are, clean. stability even concern. not slightest the data squeaky raise The very,

good by be production? would get Canada prepared when FDA, U.S. for it the plant submission lead then is is it’s the and That news. time for very ready would if And the through, take long the the does a approved a once to facility, – goes that

and timeline gearing be a speculative for really At We this I precise up little are give cannot very premature, production. would you a that point,

U.S. Hey only there in no Canada. was file is the it’s for submitted look,

right. that’s Yes,

Just to clarify.

Thank then back in And go I the Okay. will queue. you.

welcome. You are

Tubero Psychedelic two Invest. with Adam Next

open. Your line is

for Hey, me question. thank ask letting you the

time? is any let’s have for of time? question What on same time are Do Rizaport. you guys say how at strips? different same those So you manufacturing time? the other Can focus first or you the strips a manufacture at a formulation are like strips example, manufacturing just The manufacturing one of strip of at your the do many at the guys capabilities one you capabilities

Yes, that what typically do. is we

have We clients, the product one time. commercial make quarter a we would and GMT size at one

Okay. – confirmation at liberty say is Thank from you read just because to you. in question you are I they pipeline there – just know next you Can that I are confirmed what are them them. regards are things before, but the two atai, with are, on already want I’ve get you working that guys. what The the to

think I right disclose unfortunately not. compound, we don’t can now, to

say them of Is Okay. at heard a give problem. arbitration now. that is is, time we’ve long at nothing. question to guys with in last are quite on have there there you you Tilray been liberty anything update No all? because you type any And anything can My for

Sure.

So Tommy, comment. I will over to turn Tommy

been hear it’s don’t seem a actual cannot point if outside arbitration. like time compare and anything although – from the to share. we comment perspective, process long since court still And the it to this time at we for the not I I you actually you. the you little on even We’ve year a a Yes, might timing. And have it’s initiated

the than I pushing very can. be much not comment that will don’t as everything, happy The further we can as that but in arbitrator case so. have timeline It’s as necessarily we but any get that, do investor the on as cannot We’re right update, we decision anything. decides our a soon the we control. to is now

don’t questions in marijuana Okay. have the approached to have who You And or approached anything, companies? companies guys in but my strips? by you other are, guys last to been by have you two regards showing say been other interest any marijuana

We Dana, but maybe comment. you to want have been in past, the

Yes. have No, of we course times. many

still with were because bound approached them So either of we can’t yes, while we some exclusivity, current do under are partners, we have our but many we been times.

does I in if getting not last when not, terms to that’s the feel is, atai of somewhere sorry, I possible? refusal but And or sure have the question read – montelukast right access of so this I’m first

don’t no strategic of is they on first our are so. as of right agreement, I What board. I know refusal. they they have the have partnership believe part

are them being maybe us a they more didn’t So to to involved divest say And context, let’s in opportunity you before they give really little aware it. this it. of want

a at make But have be don’t we are the What first the have be right they right board. So they is decisions. refusal. to our to those on considered by and when they default, table of

they are involved. So

Awesome. Thank very much. line. I’ll you back in get

welcome You’re

take We’ll David [indiscernible]. our from question next

Your line is open.

completed call I’m regards mentioned Dr. sorry, Can patients XX trial BUENA treatment. In that [Technical XX today. enrolled. the Thank have you the completed, Zerbe, to share for patients you you The are are the Difficulty] XX

I’m sorry.

question montelukast. your really didn’t We question. You, Yes, about you I understand the off. broke get

hear okay? Can Yes. me you

Yes.

Now I okay. can. Well,

patients the you who’ve trial. Can those the any XX So share of completed patients? on XX data

Because to randomization No, blinded we and able by details look is be study would the code. breaking into fully only not. the

answer no. the So is,

you for much Thank back Okay. that. queue. very in go I’ll

You’re welcome.

now Lindsey [Private Investor]. We’ll to Murphy

open. line Your is

Thank the any discussions. my montelukast? the just montelukast, when first call. or there any companies Yes. with taking just it when for through about about Hi. Are that is question other is actually with is you discussions large pharmaceutical My

single the past We have a a we and ever before we the a was see go since the further. study we every your made the or comment very significant results very in received but interested, very saw significant to the but in before have companies, proof-of-concepts from discontinued interest have significant of can we number number those ever program, by we of commenced because we would are we contact need study, efforts, those we from any we started

and available Dana – the out being partners. the before to And hits completion reaches we – results now study road, for waiting so we’ll and of to potential before the

the how Got Thank Heritage was? order, it. you one you. can Understand. And order share question that other for large

million. Quarter

A quarter million.

Okay. so I Thank queue. go will much. you in back the

[indiscernible]. We’ll to now go

Your line is open.

Good afternoon, Dr. quick questions. Couple Zerbe.

timeline Riz the few that you a said going all having or You save not meeting was months.

think, you – exactly mean, are available? year, the what when the I now? timeline product I but said know will next do next is you I So, be think when you year

I is, I’m... believe second quarter say

Third quarter.

Would Yes. the safe quarter. Third be bed.

Okay.

Review time is months. six

and large then weeks, next preparation. time is submit, we So, review six the over months come

So QX.

RIZAPORT? orders you’re question, from if Okay. you produce if My happens, next once that Heritage, can still receiving and those additional

Yes. be shouldn’t a problem. There

Okay. flow question, be And you my when do last to expect cash positive?

That’s a question for André.

comment? So André, if you want to

Yes.

are that with two One product to products RIZAPORT. launch and We year. expecting partnered have Exeltis generic we next

So products or probably flow be if next I scheduled by, year. those should say two positive are QX cash as we QX would launched

guys. you Thank Okay.

welcome. You’re

from next comes Our question [indiscernible].

Your line is open.

resubmission I you that first Good question to for My you received, the in for Yes. Dr. CRL May is the Zerbe. regards on buprenorphine, you guys resubmission? could some light the timeline believe progress of afternoon, in and shed

don’t know pretty have is been confirm But don’t want of recently significant confidential. to that obligations. we can severe I I is all, I where confirm What that say pretty that information the from. response for product. can’t submitted that the or has that you first molecule generic I confidentiality So got

Okay.

it been to submitted So FDA? has the

Yes.

is there six timeframe month any, submission? the after review? And on your Okay. Is a it review like review

I’m sorry.

fine. That’s

review. That’s six Six months we’re what months review. expecting,

resubmitting? you resubmission, anticipate going Okay. to the you’re at I with to the RIZAPORT when you you And avoid regards batches? said that know the but FDA are time, in the do question to U.S. the meeting when next save is submit looking to

but date, the We see. I three within can next haven’t defined what precise Right. certainly it’ll from be a months

for next sure. the three months, within So

is last have I for actually more two questions. And Okay. my Tommy. Well, question

the is the in know that taking Tilray. Tommy. regards It’s but breached the I for has well. considering possibly with would you is some you with like back you as had question litigation question said the is to that ask can’t light This agreement company Tilray like I on on shed Sorry. progress, the since the them the THC exclusivity to

for have don’t rights THC. any they the So

other and way agreements able companies. to will free clear business this of you possibly, So be with know, be make Tilray to

arbitration. the on commenting Without

now going a where the outcome this will from what see looks arbitration relationship think of it is hard it’s a there’s now, IntelGenx right between and clear forward, but I assessment be, it what to I past a Tilray know the don’t looks point. meaning very right the this but at company,

For both companies actually.

Yes.

Yeah.

like Okay. to guys And public, dealing like, when see, or and be When do able going as my in in it’s that [indiscernible] know, and last submitted that think, signing like to States mean, you of I film agreement an with you like do question with Dana, we company to be about company is kind would guys so you you’re United company. for regards to the wise, the that would you timeframe when which forth? it batch

once And go full would do of to for And this product stage. will to firm ball. year. this supposed if If forward, like, way all we submitted our are assumptions, goal clear and is we full of try probably full data do we’re said, are define product a in we that to trial trying And a has deliver the of contract know the it’s we is to lot set, bit to to the the I’m, there months, Well, a the the it that waiting then we couple delivers then something find and will it. have that into but see it’s that’s first don’t worked. data I the this. reasonable agreement should there this within, see the that we film timeframe crystal has moment, the achieve they looks we met. how can if been that, a wanted the path of trial, full readout little program clinical clinical we

Okay.

October having this results In final I’m the Emery study montelukast they great. sorry, we molecule. XXXX, a supposed is think that Okay. also yield would and superior University And the has if That affect I IntelGenx? for results, delivery last is a be more coming in of regards that sounds positive IntelGenx because out mean, do they’re you doing how question. to to their platform

do positive if think out for would say think they affects? that significant they achieve that did So, example, would come you that affect like do results? How how and you

all, of monitoring first Yes, mean, their I we’re progress.

they ago October. mean, in available year first delayed. course. all, a they whenever about of to Also, expect that it Of results be I also they’re announced was or

that’s point, they’re their thinking I in this serious at they, think pretty enrollment. wishful also setbacks

due Just well we that like very mostly We honest our be coming that results the sure doing. I’m be did we will product I from so to completed. know what you the we know of the been have they’re COVID, dose much level, dosing. mean, with know they’re that will study meaningful bioavailability study there to not and before

the Book that, hold patent for does And IntelGenx Orange right?

Yes.

I For tell they’re once you we than dosing do. lower that

that the knowing a we level. higher than then know and mean, less the Now efficacy that, they to half related the we XX% that effectively we of dose the tablet, And dosing. are film have I response what neuroinflammation dose or is bioavailability the on

will we results will. these to the announce IntelGenx but that, the of from with their part qualitative comments, believe product to question, that at see your advantage, study significant but coming be to be the to IntelGenx earlier at are least back again I significantly don’t able they I a than initial So and admittedly study

Okay.

as results XX extremely and IntelGenx think the the far it to extremely, as this with higher the that for day, with chances bioavailability, at dosing successful medication? I currently with mean, are doing XX% achieve twice is see a high I I IntelGenx milligrams And Okay.

study believing. study I Yes. is with The think enough? That’s biostatistician. planned the what it the strongly we question the large was conjunction is only in population are

us the assisted So we number with up didn’t XX clinician with but have come that, patients we and to biostatistician see. yet

and the questions. want just over is so the I much forward guys. progress doing you for to you God amazing taking And Okay. company keep think I say thank And years, going bless so my

Thank very much. you

right. All

go [Operator Instructions] We’ll [indiscernible]. now to

line Your open. is

Zerbe, can hear me? you Dr. Hello,

you. hear I Yes, afternoon. Good Yes.

begin products a time This is André. cash we million; of fine. question $X today hand Most have company of burn income. for a have appears were June it of a quarter. End showed before rate discussed horizon longer the on $X to generate of Okay, they any that cash the million that a

does on appears to be capital So cash look between income close hand how start company? need of the what company additional the cash the the gap into coming amount at will to versus for when the

question. your for Thanks Yes.

have a to that tie of is in come We with January XXXX. a scheduled loan

signed So of that back. them months part we the several that was with amendment

– XXXX, commercial be in and in So of sufficient January that earlier, Rizatriptan launch get for aligned and next be products $X we year generic scheduled had to everything coming is another Like on a and to to I to XXXX us one million. XXXX able And schedule, a one we’re should two said if product. products.

– place schedule, as that about to and But takes we’re million $X that in takes we if to fine. should it as in QX year million you place $X going we of next get and So should expecting be burning we’re Because are yes, January since QX mentioned, fine. a launch be quarter.

Okay. Thank you.

to now Tom go We’ll [indiscernible].

is line open. Your

taking Yes. my call. for Thank you

other you partner the had countries. any that? call, During be going expanding if a I into our Spanish was with I marketing updates wondered there to regarding meeting last believe on

Dana? Okay,

to you Horst, me that. want take do Yes.

Yes.

did Horst European Eastern with meeting already mentioned we them. from a There quite countries. interest is So an as have

So into expand how we’re looking that. we the how work into would and timeline

for update the now. that’s So

you much. didn’t Thank you. call mentioned Okay. I very late. sorry. that got on was hear the Thank I’m I earlier.

worries. okay. It’s No

You’re welcome.

a take Adams Tobero. up We’ll follow from

Your open, line is

much. you thank Hey, so

Okay.

between far worry first get having without we was to XXXX deals what tie to much. thing enough too the in wanted call coming on just ask I said through said should be what based the the André and good a was to in profitability and so So to

deals dilution more on it’s say like something to unless assume? Let’s a that tie? that, safe in with Is

– have assume. much to There’s cash. too always safe That’s never Yes. you

at this at point, a level, money, that not necessarily stock mean doesn’t it price mean, this at we but wouldn’t I consideration. it’s this raise So,

for Zerbe. you. right, question is be going Alright, be for to my two cool. All going to next questions It’s Dr.

is, would psilocybin be So If the so a break can that on of has? first a for down what psychedelic you putting like question the IGXT me. strip advantages that

Yes.

easy to time so-called psilocybin administered Just same you oxidase strokes at in like this. a the order not is in to the In metabolite – it to if presence the likes the administer be yes, in psilocybin complicated. to let administer bloodstream lifetime in the put that Nobody monoamine make it first it you to broad concomitant administered inhibitor active medication orally order extend because makes need the of me medication just to work.

that avoid or would You by via psilocybin film. administering psilocin a

And in that’s like about tweak? type tweak to, something something guys say can would duration the film, the know be If able onset let’s But the of things it what be on would you the I you of through faster. what regards effect? putting to

to drug the occurs delivery generally there drug the optimize obviously or you what it’s the – the your deliver to the elimination Once that control bloodstream. attempt Again the in amount is speaking, delivery delivery system. to you the bloodstream. And independent system what is with completely of delivery, increase from always you increase

occurs control. it which the to system. So film is what of delivered completely optimizes our independent elimination delivery The to and from it’s bloodstream. the the Once the rate is it’s there, does extent out the drug is

Understood. Understood. Okay.

of now molecules. many now of looking [indiscernible] times sort lot And the that there’s in terms last so companies a so be into one would are in of,

matter? due – is fair these it ask duration to it there like, I even different just is would strips or completely wouldn’t So where it is compare to

I didn’t really.

on pass that [indiscernible] I enough so, to have comment question, I say to one. sorry, know don’t that on about that intelligently let’s

questions my right. for All Thank answering you doctor.

Yes.

You’re welcome.

follow Kylie. from take We’ll you up a

open is line Your

A desire questions do CRL still to approved always your to the the more the the the past Is would manufacturing RIZAPORT. for was that marketplace, me facility FDA, in all at be for to the global intent? once submitting Canadian report response a the, few gets the

is. Yes, it

the the be, my And next outstanding COVID Okay. potential – was your and that presentation, arena? the or update last, any Dr. in any That’s Parkinson’s the Bloom for then at last question which on and initiatives Zerbe would Conference, okay.

see certainly moment, be montelukast realistic. regarding you the hold. but At be COVID, to I on we’ve to for potential we do have this honest put with

for Our a of at the study. BUENA montelukast program aggressive least is, with company size, our quite

So that but would, at time at as at Parkinson and far have as I this further leave this COVID not that. go it pursuing we we’re point into not discussions,

there discussions say are me Parkinson’s. Let regarding

And your in some or Okay. Leede inquiring investor that issue I program. past André wondering, researching the other updating from research reports about just you was Jones, research houses investment out indicated had any relations we progress coming would the a report. about

this? of this over want André, André. there’s charge and would is report. comment actively André a IR nothing At I ongoing research related turn on in regarding point like to to activities. do you to further

Yes.

in expect you point or in discussion the several coverage. the in pursue been because, fall nothing roadshow several and Horst you paid probably with at banks in for discussion planning coverage. and they’re some with feel we get actively We don’t with involved which moment, this banks we’re can a at really we’ve spring banks but just any As active there’s but coverage mentioned useless,

definitive on is it nothing the So is in that, short there’s the radar. that But term.

be, the quite your And to It’s Okay. of last square would question XX,XXX addition foot facility. an is addition the storage.

Yes, it is.

But Okay.

ahead. go Andre, Okay,

the expansion future. Yes, it but for an is plan is, there

production that, go space. our in the planned, space let for using we storage, time goes capacity would couldn’t it yes, expand that we that we’re for if but as eventually everything So being,

space, other addition square XX,XXX in production to with And that’s the André?

Yes.

Wow.

Okay.

entire we space and it’s needed something with we big that The not future it’s expansion going saying project. a eventually do being that that forward are space, that tomorrow. considering I’m move it’s to But for able something to program. that we’re the to

Okay. Thank you.

welcome. You’re

We’ll Levin take follow up [ph]. Jeremy a from

Your line is open.

able in to And in and first wanted for been want afternoon. went there about what’s be you questions. to I you since free anything in why ask, of Good about but my don’t Europe. more going thanks I held sales has know haven’t the too anything appreciate to on to sort support with months it. to don’t you say last nine much, give, all just Yes. live want say been, it taking tell I I Europe. of the us can’t to, no, you

So that’s it? at the all tell first can us there question I anything Is had. you about

me take question. let Horst that

the launch the it’s we again, to you takes list meet all, marketing will performed, after pharmacy campaign. available very first it after that And of order the first the get of typically product product marketing partner product XX and from staff partner how September. in commercial September, a time it review, with the the month to and start So, with

but it that performing, leadership have that can now August compared the position market? all far So Is in is that a maxsize. variety is meeting right in companies to campaigns we is running there’s can Spain one at is of great this is down But the it August, the day, reports, maxi answer know, most you that you for, we how performing receiving the it’s It tell that end the we the of and after Spain. The see the, about if the I size product. kind taking partner, after product is product well. number alternative close first that only doing brand I in

beginning only of would an I at mostly update the in, September, of end probably So get October.

to be to certain of see can’t take it’s look marketing just couple to that months of you And the has a because at the initiatives. so lapsed, uncommon to performing. of is how first product there’s responding view lack many full predict year the product not So how really before time product the the It’s overall will communication. activities an provide

I you. that. Okay. Thank Well, okay. appreciate

a batch? is other to How of number you of long example long trips? does technical The take did for the just just of a take you I you of to it batch Like that of make more a it a order or it that weeks, manufacture just most How question more, quarter? fulfilled, is had thing. couple more

Two If to batch, to ship look the at, at weeks concrete week and analyze it. that’s we manufacture a CBD a we example. then then

about month So or it’s month is a turnaround you a, so within a

Less Yeah. than a month.

Less.

Okay. Within than a month. a month. Less

Okay.

a at sort can manufacture time, what is you that that of said product Okay. you but I and, only do? one So,

to or any So for is problem that going kind ramp that you as how up? do plan with you, to of deal you pose

and would At one three or does I mean that, I up process, weeks be on the preparing next, the out, it if timeframe then And better we blend. few the part goes it you you another gave into that week. because it machine. Not week. onto and a week, and a move packaging goes out and four the materials then with days, the, part code let’s tied leave the starts moment? the We why, again that to with not we a explain that’s the say then for coding just of breakdown dispensing about will That’s

the week the in completed been moved blending if increments pilot. we work once the because, So has material and typically can into we coding, one dispensing move next been has and can

the Of product dispensing course we the have move next to we clean, preparing can blending and then start but blend. into the next and area

see. I

intelligently, that then and that, if breakdown certain do we we really compress. a can There’s

Okay.

month, same on So be or different you two orders. three within working the can

you to, that you in If could had fit

Certainly Yes. too.

Right.

Perfect. Okay.

you. I that. Thank appreciate Okay.

Yes.

You’re welcome.

to program any like closing end approaching at our this Dr. over back or of We Zerbe I’d it are remarks. turn for to time. the additional

very Thank Yes. you much.

questions. you thank all for so your And

thank our team. directors support Investor of would continuous management board the QX It’s entire and concludes now the this to dedication, work So Update I of the for like Again, hard IntelGenx call. our team. XXXX

our supporting goodbye. Finally, to in and for in and investors continuing us. Thank believe you

for This does Thank program. participation. conclude today’s your you

at You may disconnect any time.